Triggering of suicidal erythrocyte death by topotecan

Cellular Physiology and Biochemistry

Volumn 37, Issue 4, 2015, Pages 1607-1618

  Bissinger, Rosi ^a   Bouguerra, Ghada ^b   Stockinger, Katja ^a   Abbès, Salem ^b   Lang, Florian ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b PASTEUR INSTITUTE OF TUNIS   (Tunisia)

Author keywords

Calcium; Cell volume; Ceramide; Eryptosis; Oxidative stress; Phosphatidylserine

Indexed keywords

CERAMIDE; LIPOCORTIN 5; PHOSPHATIDYLSERINE; TOPOTECAN; CALCIUM; DNA TOPOISOMERASE INHIBITOR; REACTIVE OXYGEN METABOLITE;

ARTICLE; CELL DEATH; CELL VOLUME; DRUG MECHANISM; ERYPTOSIS; ERYTHROCYTE; ERYTHROCYTE MEMBRANE; EXTRACELLULAR CALCIUM; HUMAN; HUMAN CELL; PRIORITY JOURNAL; APOPTOSIS; CELL SIZE; CYTOLOGY; DRUG EFFECTS; HEMOLYSIS; METABOLISM;

APOPTOSIS; CALCIUM; CELL SIZE; CERAMIDES; ERYTHROCYTE MEMBRANE; ERYTHROCYTES; HEMOLYSIS; HUMANS; PHOSPHATIDYLSERINES; REACTIVE OXYGEN SPECIES; TOPOISOMERASE I INHIBITORS; TOPOTECAN;

EID: 84946719872     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000438527     Document Type: Article

References (110)

1. Trojandt S, Knies D, Pektor S, Ritz S, Mailander V, Grabbe S, Reske-Kunz AB, Bros M. The chemotherapeutic agent topotecan differentially modulates the phenotype and function of dendritic cells. Cancer Immunol Immunother 2013;62:1315-1326.
2. Bryant CS, Kumar S, Spannuth W, Shah JP, Munkarah AR, Deppe G, Alvarez RD, Morris RT. Feasibility of extension of platinum-free interval with weekly bolus topotecan and subsequent platinum retreatment outcomes in recurrent ovarian cancer. Arch Gynecol Obstet 2011;283:361-367.
3. Cormio G, Loizzi V, Gissi F, Camporeale A, De Mitri P, Leone L, Putignano G, Selvaggi L. Long-Derm topotecan therapy in recurrent or persistent ovarian cancer. Eur J Gynaecol Oncol 2011;32:153-155.
4. Edwards SJ, Barton S, Thurgar E, Trevor N. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation. Health Technol Assess 2015;19:1-480.
5. Lorusso D, Pietragalla A, Mainenti S, Masciullo V, Di Vagno G, Scambia G. Review role of topotecan in gynaecological cancers: current indications and perspectives. Crit Rev Oncol Hematol 2010;74:163-174.
6. Peng LH, Chen XY, Wu TX. Topotecan for ovarian cancer. Cochrane Database Syst Rev 2008;10.1002/14651858.CD005589.pub2CD005589.
7. Sehouli J, Oskay-Ozcelik G. Current role and future aspects of topotecan in relapsed ovarian cancer. Curr Med Res Opin 2009;25:639-651.
8. Musa F, Blank S, Muggia F. A pharmacokinetic evaluation of topotecan as a cervical cancer therapy. Expert Opin Drug Metab Toxicol 2013;9:215-224.
9. Paton F, Paulden M, Saramago P, Manca A, Misso K, Palmer S, Eastwood A. Topotecan for the treatment of recurrent and stage IVB carcinoma of the cervix. Health Technol Assess 2010;14 Suppl 1:55-62.
10. Robati M, Holtz D, Dunton CJ. A review of topotecan in combination chemotherapy for advanced cervical cancer. Ther Clin Risk Manag 2008;4:213-218.
11. Mallipatna AC, Dimaras H, Chan HS, Heon E, Gallie BL. Periocular topotecan for intraocular retinoblastoma. Arch Ophthalmol 2011;129:738-745.
12. Marr BP, Brodie SE, Dunkel IJ, Gobin YP, Abramson DH. Three-drug intra-Arterial chemotherapy using simultaneous carboplatin, topotecan and melphalan for intraocular retinoblastoma: preliminary results. Br J Ophthalmol 2012;96:1300-1303.
13. Schaiquevich P, Carcaboso AM, Buitrago E, Taich P, Opezzo J, Bramuglia G, Chantada GL. Ocular pharmacology of topotecan and its activity in retinoblastoma. Retina 2014;34:1719-1727.
14. Garst J. Topotecan: An evolving option in the treatment of relapsed small cell lung cancer. Ther Clin Risk Manag 2007;3:1087-1095.
15. Hartwell D, Jones J, Loveman E, Harris P, Clegg A, Bird A. Topotecan for relapsed small cell lung cancer: a systematic review and economic evaluation. Cancer Treat Rev 2011;37:242-249.
16. Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A. The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation. Health Technol Assess 2010;14:1-204.
17. Pirker R, Berzinec P, Brincat S, Kasan P, Ostoros G, Pesek M, Plate S, Purkalne G, Rooneem R, Skrickova J, Stanculeanu D, Timcheva C, Tzekova V, Zakotnik B, Zielinski CC, Zwitter M. Therapy of small cell lung cancer with emphasis on oral topotecan. Lung Cancer 2010;70:7-13.
18. Riemsma R, Simons JP, Bashir Z, Gooch CL, Kleijnen J. Systematic Review of topotecan (Hycamtin) in relapsed small cell lung cancer. BMC Cancer 2010;10:436.
19. Kasow KA, Stewart CF, Barfield RC, Wright NL, Li C, Srivastava DK, Leung W, Horwitz EM, Bowman LC, Handgretinger R, Hale GA. A phase I/II study of CY and topotecan in patients with high-risk malignancies undergoing autologous hematopoietic cell transplantation: the St Jude long-Derm follow-up. Bone Marrow Transplant 2012;47:1448-1454.
20. Wiernik PH, Li H, Weller E, Hochster HS, Horning SJ, Nazeer T, Gordon LI, Habermann TM, Minniti CJ Jr, Shapiro GR, Cassileth PA. Activity of topotecan 21-day infusion in patients with previously treated large cell lymphoma: long-Derm follow-up of an Eastern Cooperative Oncology Group study (E5493). Leuk Lymphoma 2012;53:1137-1142.
21. Daladimos T, Theotikos E, Athanasopoulos A, Tsakonas G, Karabelis A, Mylonakis N, Kosmas C. Second high-dose chemotherapy intensification followed by hematopoietic stem cell transplantation applying a novel high-dose topotecan-based regimen in an adult Wilms' tumor patient: case report. Anticancer Drugs 2011;22:111-114.
22. Cui J, Li C, Wang C, Li Y, Zhang L, Zhang L, Xiu X, Li Y, Wei N. Nigericin-mediated liposome loading of topotecan: is nigericin a potential drug release regulator? Int J Pharm 2010;399:31-36.
23. Morgan RJ, Synold T, Mamelak A, Lim D, Al-Kadhimi Z, Twardowski P, Leong L, Chow W, Margolin K, Shibata S, Somlo G, Yen Y, Frankel P, Doroshow JH. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemother Pharmacol 2010;66:927-933.
24. Eckardt JR, von Pawel J, Pujol JL, Papai Z, Quoix E, Ardizzoni A, Poulin R, Preston AJ, Dane G, Ross G. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol 2007;25:2086-2092.
25. Hormann V, Kumi-Diaka J, Durity M, Rathinavelu A. Anticancer activities of genistein-Dopotecan combination in prostate cancer cells. J Cell Mol Med 2012;16:2631-2636.
26. Khalife R, Stephany el H, Tarras O, Hodroj MH, Rizk S. Antiproliferative and proapoptotic effects of topotecan in combination with thymoquinone on acute myelogenous leukemia. Clin Lymphoma Myeloma Leuk 2014;14 Suppl:S46-55.
27. Kim MK, James J, Annunziata CM. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells. BMC Cancer 2015;15:196.
28. Gantar M, Dhandayuthapani S, Rathinavelu A. Phycocyanin induces apoptosis and enhances the effect of topotecan on prostate cell line LNCaP. J Med Food 2012;15:1091-1095.
29. Schumacher M, Hautzinger A, Rossmann A, Holzhauser S, Popovic D, Hertrampf A, Kuntz S, Boll M, Wenzel U. Chrysin blocks topotecan-induced apoptosis in Caco-2 cells in spite of inhibition of ABC-Dransporters. Biochem Pharmacol 2010;80:471-479.
30. Tsang PS, Cheuk AT, Chen QR, Song YK, Badgett TC, Wei JS, Khan J. Synthetic lethal screen identifies NF-kappaB as a target for combination therapy with topotecan for patients with neuroblastoma. BMC Cancer 2012;12:101.
31. Wang Y, Peng RQ, Li DD, Ding Y, Wu XQ, Zeng YX, Zhu XF, Zhang XS. Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells. Chin J Cancer 2011;30:690-700.
32. Zhang M, Shan BE, Yuan NF, Liu W. Effect of topotecan on retinocytoma cell apoptosis and expression of Livin and PTEN. Chin Med J (Engl) 2013;126:340-344.
33. Zhang Y, Chen X, Ren P, Su Z, Cao H, Zhou J, Zou X, Fu S, Lin S, Fan J, Yang B, Sun X, Zhou Y, Chen Y, Yang L, Wu J. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2013;87:356-362.
34. Dudas J, Bocsi J, Fullar A, Baghy K, Fule T, Kudaibergenova S, Kovalszky I. Heparin and liver heparan sulfate can rescue hepatoma cells from topotecan action. Biomed Res Int 2014;2014:765794.
35. Sato A, Asano T, Horiguchi A, Ito K, Sumitomo M, Asano T. Antitumor effect of suberoylanilide hydroxamic acid and topotecan in renal cancer cells. Oncol Res 2011;19:217-223.
36. Tsunetoh S, Terai Y, Sasaki H, Tanabe A, Tanaka Y, Sekijima T, Fujioka S, Kawaguchi H, Kanemura M, Yamashita Y, Ohmichi M. Topotecan as a molecular targeting agent which blocks the Akt and VEGF cascade in platinum-resistant ovarian cancers. Cancer Biol Ther 2010;10:1137-1146.
37. Zhang FL, Wang P, Liu YH, Liu LB, Liu XB, Li Z, Xue YX. Topoisomerase I inhibitors, shikonin and topotecan, inhibit growth and induce apoptosis of glioma cells and glioma stem cells. PLoS One 2013;8:e81815.
38. Sottile F, Gnemmi I, Cantilena S, D'Acunto WC, Sala A. A chemical screen identifies the chemotherapeutic drug topotecan as a specific inhibitor of the B-MYB/MYCN axis in neuroblastoma. Oncotarget 2012;3:535-545.
39. Lang PA, Kaiser S, Myssina S, Wieder T, Lang F, Huber SM. Role of Ca2+-Activated K+ channels in human erythrocyte apoptosis. Am J Physiol Cell Physiol 2003;285:C1553-C1560.
40. Lang E, Qadri SM, Lang F. Killing me softly-suicidal erythrocyte death. Int J Biochem Cell Biol 2012;44:1236-1243.
41. Abed M, Towhid ST, Mia S, Pakladok T, Alesutan I, Borst O, Gawaz M, Gulbins E, Lang F. Sphingomyelinase-induced adhesion of eryptotic erythrocytes to endothelial cells. Am J Physiol Cell Physiol 2012;303:C991-999.
42. Lau IP, Chen H, Wang J, Ong HC, Leung KC, Ho HP, Kong SK. In vitro effect of CTAB-And PEG-coated gold nanorods on the induction of eryptosis/erythroptosis in human erythrocytes. Nanotoxicology 2012;6:847-856.
43. Maellaro E, Leoncini S, Moretti D, Del Bello B, Tanganelli I, De Felice C, Ciccoli L. Erythrocyte caspase-3 activation and oxidative imbalance in erythrocytes and in plasma of type 2 diabetic patients. Acta Diabetol 2013;50:489-495.
44. Kucherenko Y, Zelenak C, Eberhard M, Qadri SM, Lang F. Effect of casein kinase 1alpha activator pyrvinium pamoate on erythrocyte ion channels. Cell Physiol Biochem 2012;30:407-417.
45. Zelenak C, Eberhard M, Jilani K, Qadri SM, Macek B, Lang F. Protein kinase CK1alpha regulates erythrocyte survival. Cell Physiol Biochem 2012;29:171-180.
46. Bhavsar SK, Gu S, Bobbala D, Lang F. Janus kinase 3 is expressed in erythrocytes, phosphorylated upon energy depletion and involved in the regulation of suicidal erythrocyte death. Cell Physiol Biochem 2011;27:547-556.
47. Klarl BA, Lang PA, Kempe DS, Niemoeller OM, Akel A, Sobiesiak M, Eisele K, Podolski M, Huber SM, Wieder T, Lang F. Protein kinase C mediates erythrocyte 'programmed cell death' following glucose depletion. Am J Physiol Cell Physiol 2006;290:C244-253.
48. Gatidis S, Zelenak C, Fajol A, Lang E, Jilani K, Michael D, Qadri SM, Lang F: p38 MAPK activation and function following osmotic shock of erythrocytes. Cell Physiol Biochem 2011;28:1279-1286.
49. Zelenak C, Foller M, Velic A, Krug K, Qadri SM, Viollet B, Lang F, Macek B. Proteome analysis of erythrocytes lacking AMP-Activated protein kinase reveals a role of PAK2 kinase in eryptosis. J Proteome Res 2011;10:1690-1697.
50. Foller M, Sopjani M, Koka S, Gu S, Mahmud H, Wang K, Floride E, Schleicher E, Schulz E, Munzel T, Lang F. Regulation of erythrocyte survival by AMP-Activated protein kinase. FASEB J 2009;23:1072-1080.
51. Foller M, Feil S, Ghoreschi K, Koka S, Gerling A, Thunemann M, Hofmann F, Schuler B, Vogel J, Pichler B, Kasinathan RS, Nicolay JP, Huber SM, Lang F, Feil R. Anemia and splenomegaly in cGKI-deficient mice. Proc Natl Acad Sci U S A 2008;105:6771-6776.
52. Lupescu A, Shaik N, Jilani K, Zelenak C, Lang E, Pasham V, Zbidah M, Plate A, Bitzer M, Foller M, Qadri SM, Lang F. Enhanced erythrocyte membrane exposure of phosphatidylserine following sorafenib treatment: an in vivo and in vitro study. Cell Physiol Biochem 2012;30:876-888.
53. Shaik N, Lupescu A, Lang F. Sunitinib-sensitive suicidal erythrocyte death. Cell Physiol Biochem 2012;30:512-522.
54. Jilani K, Qadri SM, Lang F. Geldanamycin-induced phosphatidylserine translocation in the erythrocyte membrane. Cell Physiol Biochem 2013;32:1600-1609.
55. Vota DM, Maltaneri RE, Wenker SD, Nesse AB, Vittori DC. Differential erythropoietin action upon cells induced to eryptosis by different agents. Cell Biochem Biophys 2013;65:145-157.
56. Zappulla D. Environmental stress, erythrocyte dysfunctions, inflammation, and the metabolic syndrome: adaptations to CO2 increases? J Cardiometab Syndr 2008;3:30-34.
57. Zbidah M, Lupescu A, Jilani K, Lang F. Stimulation of suicidal erythrocyte death by fumagillin. Basic Clin Pharmacol Toxicol 2013;112:346-351.
58. Abed M, Herrmann T, Alzoubi K, Pakladok T, Lang F. Tannic Acid induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:1106-1116.
59. Ahmed MS, Langer H, Abed M, Voelkl J, Lang F. The uremic toxin acrolein promotes suicidal erythrocyte death. Kidney Blood Press Res 2013;37:158-167.
60. Ghashghaeinia M, Cluitmans JC, Toulany M, Saki M, Koberle M, Lang E, Dreischer P, Biedermann T, Duszenko M, Lang F, Bosman GJ, Wieder T. Age Sensitivity of NFkappaB Abundance and Programmed Cell Death in Erythrocytes Induced by NFkappaB Inhibitors. Cell Physiol Biochem 2013;32:801-813.
61. Alzoubi K, Honisch S, Abed M, Lang F. Triggering of Suicidal Erythrocyte Death by Penta-O-galloyl-beta-d-glucose. Toxins (Basel) 2014;6:54-65.
62. Jilani K, Lang F. Carmustine-induced phosphatidylserine translocation in the erythrocyte membrane. Toxins (Basel) 2013;5:703-716.
63. Jilani K, Enkel S, Bissinger R, Almilaji A, Abed M, Lang F. Fluoxetine induced suicidal erythrocyte death. Toxins (Basel) 2013;5:1230-1243.
64. Lupescu A, Bissinger R, Jilani K, Lang F. Triggering of suicidal erythrocyte death by celecoxib. Toxins (Basel) 2013;5:1543-1554.
65. Lupescu A, Jilani K, Zbidah M, Lang F. Patulin-induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:291-299.
66. Abed M, Zoubi KA, Theurer M, Lang F. Effect of dermaseptin on erythrocytes. Basic Clin Pharmacol Toxicol 2013;113:347-352.
67. Arnold M, Lang E, Modicano P, Bissinger R, Faggio C, Abed M, Lang F. Effect of nitazoxanide on erythrocytes. Basic Clin Pharmacol Toxicol 2014;114:421-426.
68. Oswald G, Alzoubi K, Abed M, Lang F. Stimulation of suicidal erythrocyte death by ribavirin. Basic Clin Pharmacol Toxicol 2014;114:311-317.
69. Bissinger R, Malik A, Jilani K, Lang F. Triggering of Erythrocyte Cell Membrane Scrambling by Salinomycin. Basic Clin Pharmacol Toxicol 2014;10.1111/bcpt.12250
70. Abed M, Feger M, Alzoubi K, Pakladok T, Frauenfeld L, Geiger C, Towhid ST, Lang F. Sensitization of erythrocytes to suicidal erythrocyte death following water deprivation. Kidney Blood Press Res 2013;37:567-578.
71. Alzoubi K, Calabrà S, Bissinger R, Abed M, Faggio C, Lang F. Stimulation of Suicidal Erythrocyte Death by Artesunate. Cell Physiol Biochem 2014;34:2232-2244.
72. Arnold M, Bissinger R, Lang F. Mitoxantrone-induced suicidal erythrocyte death. Cell Physiol Biochem 2014;34:1756-1767.
73. Bissinger R, Fischer S, Jilani K, Lang F. Stimulation of Erythrocyte Death by Phloretin. Cell Physiol Biochem 2014;34:2256-2265.
74. Bissinger R, Lupescu A, Zelenak C, Jilani K, Lang F. Stimulation of eryptosis by cryptotanshinone. Cell Physiol Biochem 2014;34:432-442.
75. Bissinger R, Modicano P, Frauenfeld L, Lang E, Jacobi J, Faggio C, Lang F. Estramustine-induced suicidal erythrocyte death. Cell Physiol Biochem 2013;32:1426-1436.
76. Jacobi J, Lang E, Bissinger R, Frauenfeld L, Modicano P, Faggio C, Abed M, Lang F. Stimulation of erythrocyte cell membrane scrambling by mitotane. Cell Physiol Biochem 2014;33:1516-1526.
77. Lupescu A, Bissinger R, Herrmann T, Oswald G, Jilani K, Lang F. Induction of suicidal erythrocyte death by novobiocin. Cell Physiol Biochem 2014;33:670-680.
78. Lupescu A, Bissinger R, Warsi J, Jilani K, Lang F. Stimulation of erythrocyte cell membrane scrambling by gedunin. Cell Physiol Biochem 2014;33:1838-1848.
79. Malik A, Bissinger R, Calabro S, Faggio C, Jilani K, Lang F. Aristolochic Acid Induced Suicidal Erythrocyte Death. Kidney Blood Press Res 2014;39:408-419.
80. Tesoriere L, Attanzio A, Allegra M, Cilla A, Gentile C, Livrea MA. Oxysterol mixture in hypercholesterolemia-relevant proportion causes oxidative stress-dependent eryptosis. Cell Physiol Biochem 2014;34:1075-1089.
81. Voelkl J, Alzoubi K, Mamar AK, Ahmed MS, Abed M, Lang F. Stimulation of suicidal erythrocyte death by increased extracellular phosphate concentrations. Kidney Blood Press Res 2013;38:42-51.
82. Zhang R, Xiang Y, Ran Q, Deng X, Xiao Y, Xiang L, Li Z. Involvement of calcium, reactive oxygen species, and ATP in hexavalent chromium-induced damage in red blood cells. Cell Physiol Biochem 2014;34:1780-1791.
83. Alzoubi K, Calabro S, Egler J, Faggio C, Lang F. Triggering of programmed erythrocyte death by alantolactone. Toxins (Basel) 2014;6:3596-3612.
84. Faggio C, Alzoubi K, Calabro S, Lang F. Stimulation of suicidal erythrocyte death by PRIMA-1. Cell Physiol Biochem 2015;35:529-540.
85. Buitrago E, Hocht C, Chantada G, Fandino A, Navo E, Abramson DH, Schaiquevich P, Bramuglia GF. Pharmacokinetic analysis of topotecan after intra-vitreal injection. Implications for retinoblastoma treatment. Exp Eye Res 2010;91:9-14.
86. Abed M, Artunc F, Alzoubi K, Honisch S, Baumann D, Foller M, Lang F. Suicidal erythrocyte death in end-stage renal disease. J Mol Med (Berl) 2014;92:871-879.
87. Calderon-Salinas JV, Munoz-Reyes EG, Guerrero-Romero JF, Rodriguez-Moran M, Bracho-Riquelme RL, Carrera-Gracia MA, Quintanar-Escorza MA. Eryptosis and oxidative damage in type 2 diabetic mellitus patients with chronic kidney disease. Mol Cell Biochem 2011;357:171-179.
88. Polak-Jonkisz D, Purzyc L. Ca(2+) influx versus efflux during eryptosis in uremic erythrocytes. Blood Purif 2012;34:209-210; author reply 210.
89. Lang PA, Beringer O, Nicolay JP, Amon O, Kempe DS, Hermle T, Attanasio P, Akel A, Schafer R, Friedrich B, Risler T, Baur M, Olbricht CJ, Zimmerhackl LB, Zipfel PF, Wieder T, Lang F. Suicidal death of erythrocytes in recurrent hemolytic uremic syndrome. J Mol Med (Berl) 2006;84:378-388.
90. Nicolay JP, Schneider J, Niemoeller OM, Artunc F, Portero-Otin M, Haik G, Jr., Thornalley PJ, Schleicher E, Wieder T, Lang F. Stimulation of suicidal erythrocyte death by methylglyoxal. Cell Physiol Biochem 2006;18:223-232.
91. Lang E, Gatidis S, Freise NF, Bock H, Kubitz R, Lauermann C, Orth HM, Klindt C, Schuier M, Keitel V, Reich M, Liu G, Schmidt S, Xu HC, Qadri SM, Herebian D, Pandyra AA, Mayatepek E, Gulbins E, Lang F, Haussinger D, Lang KS, Foller M, Lang PA. Conjugated bilirubin triggers anemia by inducing erythrocyte death. Hepatology 2015;61:275-284.
92. Qadri SM, Mahmud H, Lang E, Gu S, Bobbala D, Zelenak C, Jilani K, Siegfried A, Foller M, Lang F. Enhanced suicidal erythrocyte death in mice carrying a loss-of-function mutation of the adenomatous polyposis coli gene. J Cell Mol Med 2012;16:1085-1093.
93. Kempe DS, Akel A, Lang PA, Hermle T, Biswas R, Muresanu J, Friedrich B, Dreischer P, Wolz C, Schumacher U, Peschel A, Gotz F, Doring G, Wieder T, Gulbins E, Lang F. Suicidal erythrocyte death in sepsis. J Mol Med (Berl) 2007;85:273-281.
94. Lang PA, Schenck M, Nicolay JP, Becker JU, Kempe DS, Lupescu A, Koka S, Eisele K, Klarl BA, Rubben H, Schmid KW, Mann K, Hildenbrand S, Hefter H, Huber SM, Wieder T, Erhardt A, Haussinger D, Gulbins E, Lang F. Liver cell death and anemia in Wilson disease involve acid sphingomyelinase and ceramide. Nat Med 2007;13:164-170.
95. Harrison HE, Bunting H, Ordway NK, Albrink WS. The Pathogenesis of the Renal Injury Produced in the Dog by Hemoglobin or Methemoglobin. J Exp Med 1947;86:339-356.
96. Foller M, Bobbala D, Koka S, Huber SM, Gulbins E, Lang F. Suicide for survival-death of infected erythrocytes as a host mechanism to survive malaria. Cell Physiol Biochem 2009;24:133-140.
97. Kirk K. Membrane transport in the malaria-infected erythrocyte. Physiol Rev 2001;81:495-537.
98. Ayi K, Giribaldi G, Skorokhod A, Schwarzer E, Prendergast PT, Arese P: 16alpha-bromoepiandrosterone, an antimalarial analogue of the hormone dehydroepiandrosterone, enhances phagocytosis of ring stage parasitized erythrocytes: a novel mechanism for antimalarial activity. Antimicrob Agents Chemother 2002;46:3180-3184.
99. Ayi K, Turrini F, Piga A, Arese P. Enhanced phagocytosis of ring-parasitized mutant erythrocytes: a common mechanism that may explain protection against falciparum malaria in sickle trait and beta-Dhalassemia trait. Blood 2004;104:3364-3371.
100. Cappadoro M, Giribaldi G, O'Brien E, Turrini F, Mannu F, Ulliers D, Simula G, Luzzatto L, Arese P. Early phagocytosis of glucose-6-phosphate dehydrogenase (G6PD)-deficient erythrocytes parasitized by Plasmodium falciparum may explain malaria protection in G6PD deficiency. Blood 1998;92:2527-2534.
101. Koka S, Huber SM, Boini KM, Lang C, Foller M, Lang F. Lead decreases parasitemia and enhances survival of Plasmodium berghei-infected mice. Biochem Biophys Res Commun 2007;363:484-489.
102. Koka S, Lang C, Niemoeller OM, Boini KM, Nicolay JP, Huber SM, Lang F. Influence of NO synthase inhibitor L-NAME on parasitemia and survival of Plasmodium berghei infected mice. Cell Physiol Biochem 2008;21:481-488.
103. Borst O, Abed M, Alesutan I, Towhid ST, Qadri SM, Foller M, Gawaz M, Lang F. Dynamic adhesion of eryptotic erythrocytes to endothelial cells via CXCL16/SR-PSOX. Am J Physiol Cell Physiol 2012;302:C644-C651.
104. Andrews DA, Low PS. Role of red blood cells in thrombosis. Curr Opin Hematol 1999;6:76-82.
105. Chung SM, Bae ON, Lim KM, Noh JY, Lee MY, Jung YS, Chung JH. Lysophosphatidic acid induces thrombogenic activity through phosphatidylserine exposure and procoagulant microvesicle generation in human erythrocytes. Arterioscler Thromb Vasc Biol 2007;27:414-421.
106. Zwaal RF, Comfurius P, Bevers EM. Surface exposure of phosphatidylserine in pathological cells. Cell Mol Life Sci 2005;62:971-988.
107. Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol 1999;107:300-302.
108. Gallagher PG, Chang SH, Rettig MP, Neely JE, Hillery CA, Smith BD, Low PS. Altered erythrocyte endothelial adherence and membrane phospholipid asymmetry in hereditary hydrocytosis. Blood 2003;101:4625-4627.
109. Pandolfi A, Di Pietro N, Sirolli V, Giardinelli A, Di Silvestre S, Amoroso L, Di Tomo P, Capani F, Consoli A, Bonomini M. Mechanisms of uremic erythrocyte-induced adhesion of human monocytes to cultured endothelial cells. J Cell Physiol 2007;213:699-709.
110. Wood BL, Gibson DF, Tait JF. Increased erythrocyte phosphatidylserine exposure in sickle cell disease: flow-cytometric measurement and clinical associations. Blood 1996;88:1873-1880.